Apyx Medical (NASDAQ:APYX) Shares Down 1.8% – Time to Sell?

Apyx Medical Corporation (NASDAQ:APYX) shares traded down 1.8% on Friday . The stock traded as low as $4.34 and last traded at $4.38. 43,859 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 109,807 shares. The stock had previously closed at $4.46.

Analyst Ratings Changes

A number of brokerages have recently issued reports on APYX. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Apyx Medical Trading Down 1.8%

The stock’s 50-day simple moving average is $4.14 and its two-hundred day simple moving average is $3.88. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79. The firm has a market capitalization of $183.57 million, a P/E ratio of -19.91 and a beta of 1.37.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million for the quarter, compared to the consensus estimate of $10.53 million.

Hedge Funds Weigh In On Apyx Medical

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of Apyx Medical during the 3rd quarter valued at about $28,000. Nwam LLC bought a new stake in Apyx Medical during the first quarter worth approximately $47,000. Osaic Holdings Inc. purchased a new stake in Apyx Medical during the second quarter valued at approximately $50,000. Franklin Resources Inc. bought a new stake in shares of Apyx Medical in the 3rd quarter valued at approximately $59,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Apyx Medical in the 4th quarter valued at approximately $73,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.